MedTrace Logo

Precision-Panc Master Protocol: Personalising Treatment for Pancreatic Cancer

NCT04161417 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 2500

Last updated 2024-02-08

No results posted yet for this study

Summary

The Precision-Panc Master Protocol is a "portal" protocol for patients with known or suspected pancreatic cancer to be accrued through multiple centres in the UK, with the option of being subsequently enrolled into PRIMUS (Pancreatic canceR Individualised Multi-arm Umbrella Studies) examining different treatment regimens and/or biomarker development. Eligible patients will undergo tumour biopsy and blood collection prospectively for molecular profiling at a central laboratory and the results may be used to inform enrolment to PRIMUS studies.

Conditions

  • Neoplasms Pancreatic

Interventions

OTHER

Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling

Patients with suspected or confirmed pancreatic cancer will be be asked to provide biopsy material for molecular profiling. This will enable patient enrolment into a currently available PRIMUS study

Sponsors & Collaborators

  • Cancer Research UK

    collaborator OTHER

  • NHS Greater Glasgow and Clyde

    collaborator OTHER

  • Judith Dixon-Hughes

    lead OTHER

Principal Investigators

  • David Chang · University of Glasgow

  • Juan Valle · University of Manchester

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-28
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04161417 on ClinicalTrials.gov